Deutsche Bank Comments On Merck And Roche Collaboration

According to Deutsche Bank, Merck & Co (NYSE: MRK) announced this week that they had established a broad HCV alliance, across all major facets of the therapeutic area, including marketing, diagnostics, and R&D.

Deutsche Bank said that as part of the agreement, Roche will co-promote MRK's Victrelis in the US and the companies will work together to improve HCV awareness, diagnosis, and treatment in this market. “In addition, they intend to extend their alliance to other developed and emerging markets.”

Merck & Co closed yesterday at $37.27.